Drug Profile
Jaktinib - Suzhou Zelgen Biopharmaceuticals
Alternative Names: Jakotinib hydrochloride; Jaktinib dihydrochloride monohydrateLatest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator Suzhou Zelgen Biopharmaceuticals
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antipsoriatics; Antivirals; Skin disorder therapies; Small molecules
- Mechanism of Action ACVR1 protein inhibitors; Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Myelofibrosis
- Phase III Alopecia areata; Ankylosing spondylitis; Atopic dermatitis
- Phase II Idiopathic pulmonary fibrosis; Plaque psoriasis
- Phase I/II Myelodysplastic syndromes
- Phase I Autoimmune disorders; Systemic lupus erythematosus
- No development reported Cancer; COVID-19 pneumonia
Most Recent Events
- 18 Mar 2024 Suzhou Zelgen Biopharmaceuticals initiates a phase I trial (In volunteers) in China (PO, Tablet) (NCT06193148)
- 08 Jan 2024 Suzhou Zelgen Biopharmaceuticals plans a phase I trial (In volunteers) in China (PO, Tablet) (NCT06193148)
- 20 Dec 2023 Suzhou Zelgen Biopharmaceuticals completes enrolment in a phase I trial (In volunteers) in China (PO, Tablet) (NCT06132243)